Indeed, the identification of CpG +314 and +332 hypermethylation at p15INK4b is of important value, whereas two sites seem incapable of remarkably attenuating p15INK4b expression in CAD patients compared with controls. This evidence concerns the gene CDKN2B and coronary artery disorder.